FDA Flags Over 40 Pain and Arthritis Supplements Containing Undisclosed Drug Ingredients

The FDA's expanding list of adulterated pain and arthritis supplements now exceeds 40 flagged products, placing supply chain integrity and market surveillance squarely on the agenda for QA directors and regulatory affairs leads operating in the OTC and dietary supplement space. Products marketed as natural arthritis and inflammation remedies have been found to contain undisclosed pharmaceutical ingredients, constituting medication health fraud under federal definitions.

The agency's Health Fraud Product Database documents notifications stretching from mid-2023 through May 2026, with the most recent public notification issued 15 May 2026 for Sâm Xương Khớp Ông Tiên. Earlier April 2026 notifications covered seven additional products, including Yeicob Ácido Hialurónico, KUKA FLEX CBD, and RM Joe. The breadth of the list reflects a sustained enforcement posture rather than a single enforcement action.

For manufacturers of legitimate analgesic and anti-inflammatory drug products, the regulatory burden is practical: distinguishing compliant, 21 CFR Part 211-manufactured products from fraudulent market entrants requires active engagement with distributor qualification and incoming material verification. Where supply chains intersect with contract manufacturers or third-party logistics providers sourcing from international markets, the risk of co-mingling or misrepresentation is non-trivial.

The FDA explicitly notes that its published list covers only a fraction of contaminated products in circulation, and absence from the database does not constitute a safety determination. That caveat carries weight for QA teams conducting supplier audits or reviewing certificate-of-analysis documentation for raw materials sourced from regions represented heavily in the flagged product list. Several notified products carry Spanish- and Vietnamese-language branding, suggesting distribution channels that may overlap with legitimate ethnic-market retail networks.

Plant heads managing packaging lines for dietary supplement contract manufacturing should review labeling controls and incoming goods inspection protocols against the adulteration provisions of 21 CFR Part 111, which governs current good manufacturing practice for dietary supplements, to ensure no undeclared active pharmaceutical ingredients enter the production stream.

The pace of new notifications, averaging several per quarter across the review period, indicates the FDA's surveillance program is active and expanding, making periodic cross-referencing of the Health Fraud Product Database a defensible element of any supplier qualification procedure.

Source: U.S. Food and Drug Administration, Medication Health Fraud Notifications page, via FDA.gov, 15 May 2026.